drugset
Drugs / TQB3909
last change 10 days ago re-read 9 days ago

TQB3909

targets BCL2 via inhibition

Developed for
cancer · breast cancer · chronic lymphocytic leukemia/small lymphocytic lymphoma · hematopoietic and lymphoid cell neoplasm · mantle cell lymphoma · myeloid neoplasm
Investigated by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Trials 7

today NCT07011186 · Ph 1/2 NCT06211751 · Ph 1 NCT06165822 · Ph 1 NCT05959694 · Ph 1/2 NCT06106841 · Ph 1/2 NCT05775575 · Ph 1/2 NCT04975204 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT06211751 Jan 2024 → Dec 2025 hematopoietic and lymphoid cell neoplasm Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 1 NCT06165822 Dec 2023 → Jan 2024 cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04975204 Feb → Dec 2022 cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT07011186 Apr 2024 → Oct 2025 overdue myeloid neoplasm Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT05959694 Oct 2023 → Dec 2025 chronic lymphocytic leukemia/small lymphocytic lymphoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 1/2 NCT06106841 Oct 2023 → Oct 2024 mantle cell lymphoma Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Terminated No outcome recorded Stop: Business
Phase 1/2 NCT05775575 Mar → Dec 2023 breast cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Comparator or background therapy1 trial
Phase 1/2 NCT06245941 Background May 2024 → Dec 2025 myelofibrosis Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Terminated No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2024-11-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results 正大天晴7大创新药亮相ASH 2024，展现血液病领域突破性进展 cttq.com ↗
TQB3909更新了其在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）中的研究数据，有望为BTK抑制剂耐药的CLL/SLL患者提供新的治疗选择。

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as TQB3909 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05959694 ↗
7

NCT06245941 ↗

NCT06165822 ↗

NCT06106841 ↗

NCT06211751 ↗

NCT04975204 ↗

NCT05775575 ↗

NCT07011186 ↗
Action Inhibit “TQB3909 is an inhibitor targeting BCL-2 protein” NCT04975204 ↗
Route Oral “Oral administration on an empty stomach” NCT04975204 ↗
Target BCL2 “TQB3909 is an inhibitor targeting BCL-2 protein” NCT04975204 ↗